BMY’s Pullback Lures Dip Buyers but DeepValue Report Warns Margin Bridge Is Untested

What happened

Bristol Myers Squibb's recent pullback to a forward P/E of 8.7x and a 4.6% dividend yield has attracted value-oriented investors, with Seeking Alpha arguing the sell-off is a gift for long-term holders. The bull case rests on a 9% YoY sales expansion in BMY's growth portfolio and a pipeline set for pivotal data in the second half of 2026. However, our latest DeepValue Master Report maintains a WAIT rating at $60.46, emphasizing that the 2026 ‘bridge year’ is fragile due to IRA-driven price resets for Eliquis and a January 31, 2026 step-change in Revlimid generic competition. We see no evidence that these policy and competitive forces have been neutralized, and the company’s guided non-GAAP gross margin of 69–70% may prove difficult to hold if Eliquis growth is achieved via gross-to-net concessions. Until Q1–Q2 2026 results confirm that Eliquis can meet its 10–15% growth target without margin deterioration, the pullback remains a trap rather than a gift.

Implication

Near-term, the stock at 8.7x earnings offers a cheap entry only if the Eliquis bridge holds—but the risk of a gross margin miss is real. Over a multi-year horizon, BMY’s Growth Portfolio and pipeline could justify a higher multiple, but only after the IRA and Revlimid headwinds are demonstrably managed. The dividend appears safe, but upside is capped until the 2H26 readouts (milvexian, Cobenfy) de-risk the post-bridge growth story. We would get more constructive if Q1 2026 results show non-GAAP gross margin at or above 69% alongside Eliquis sales tracking 10–15% growth. Absent that, the stock could re-rate toward our $52 bear case if margins break below 69%.

Thesis delta

The Seeking Alpha article frames the pullback as a buying opportunity based on low valuation and growth portfolio momentum. Our analysis does not dispute the growth portfolio's strength, but we view the policy-driven margin compression and Revlimid acceleration as unresolved risks that could throttle earnings power in 2026. This introduces a thesis delta: while the growth story is intact, the quality of Eliquis growth and its impact on gross margins must be verified before the stock can re-rate toward $65+. The investor must choose between a seemingly cheap stock and an unconfirmed earnings bridge.